13 February 2025 - Fabhalta is the first oral monotherapy for previously treated and treatment naïve adults with paroxysmal nocturnal haemoglobinuria.

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta (iptacopan capsules) as the first oral monotherapy treatment for adult patients with paroxysmal nocturnal haemoglobinuria who have haemolytic anaemia.

Read Novartis press release